86823-81-6

Basic information

• Product Name: Benzoic acid, 2-(bromomethyl)-6-methoxy-, ethyl ester
• Synonyms: ethyl 3-O-methyl-6-bromomethylsalicylate;ethyl 2-(bromomethyl)-6-methoxybenzoate;2-bromomethyl-6-methoxy-benzoic acid ethyl ester;ethyl 2-bromomethyl-6-methoxybenzoate;2-Brommethyl-6-methoxybenzoesaeureethylester;2-(bromomethyl)-6-methoxybenzoic acid ethyl ester
• CAS NO: 86823-81-6
• Molecular Formula: C11H13BrO3
• Molecular Weight: 273.126
• Mol File: 86823-81-6.mol
• Article Data: 10

Chemical Properties

• CAS DataBase Reference: Benzoic acid, 2-(bromomethyl)-6-methoxy-, ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 2-(bromomethyl)-6-methoxy-, ethyl ester(86823-81-6)
• EPA Substance Registry System: Benzoic acid, 2-(bromomethyl)-6-methoxy-, ethyl ester(86823-81-6)

Safety Data

• Hazardous Substances Data: 86823-81-6(Hazardous Substances Data)

Upstream product

• 6520-83-8 ethyl 2-methoxy-6-methylbenzoate 
• 6555-40-4 ethyl 2-hydroxy-6-methylbenzoate 
• 34241-39-9 azobisisobutyronitrile 

Downstream Products

• 145103-20-4 2-Benzoyl-1-(2-carbethoxy-3-methoxybenzyl)-1-cyan-1,2-dihydroisochinolin 
• 118842-83-4 (2-Ethoxycarbonyl-3-methoxybenzyl)triphenylphosphoniumbromid 
• 857652-04-1 2-(bromomethyl)-6-methoxybenzyl alcohol 
• 857651-69-5 2-bromomethyl-6-methoxy-benzaldehyde 
• 86823-82-7 ethyl 2-(bromocyanomethyl)-6-methoxybenzoate 
• 1033809-93-6 7-hydroxy-2-methyl-2,3-dihydroisoindol-1-one 

Relevant articles and documents

DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED PATHOLOGIES

Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds are disclosed that are represented by general formula (I). Also disclosed, are pharmaceutical compositions including these compounds and methods of using these compounds and compositions for the

Method of inhibiting protein tyrosine phosphatase 1B and/or T-cell protein tyrosine phosphatase 4 and/or other PTPases with an Asp residue at position 48

The present invention provides a method of inhibiting a member of a family of Protein Tyrosine Phosphatases (PTPases, PTPs) such as PTP1B, TC-PTP, CD45, SHP-1, SHP-2, PTPα, PTPε, PTPμ, PTPδ, PTPσ, PTPζ, PTPβ, PTPD1, PTPD2, PTPH1, PTP-MEG1, PTP-LAR, and HePTP by exposing said Ptpase member by administration to a host or otherwise to at least one compound with certain structural, physical and spatial characteristics that allow for the interaction of said compound with specific residues of the active site of PTP1B and/or TC-PTP. These compounds are indicated in the management or treatment of a broad range of diseases such as autoimmune diseases, acute and chronic inflammation, osteoporosis, various forms of cancer and malignant diseases, and type I diabetes and type II diabetes, as well as in the isolation of PTPases and in elucidation or further elucidation of their biological function.

Protoberberines from Reissert-Compounds VIII [1]. Oxazoloisoquinolines, New and Efficient Educts for the Synthesis of 8-Oxoprotoberberines

Certain benzylated oxazoloisoquinolinones readily available from Reissert compounds provided an efficient access to 8-oxoprotoberberines in three steps. A series of these new precursors as well as several oxoprotoberberines were prepared and the scope and limitation of this procedure were investigated.